Home Health CNBG releases world’s first study on monkeypox-specific mRNA vaccines, proves efficacy, safety

CNBG releases world’s first study on monkeypox-specific mRNA vaccines, proves efficacy, safety

by News Desk
0 comment

monkeypox

A Chinese-developed monkeypox-specific mRNA vaccine has proven to be highly effective in protecting mice from lethal doses of the virus, according to a study recently published by China, which could potentially lead to monkeypox in the future. are potential candidates to help prepare the world for the epidemic of The Chinese state-owned he is the National Biotec Group (CNBG) under Sinopharm.

The study, which was posted on the preprint platform bioRxiv on November 22 by a research team led by CNBG Chairman Yang Shaoming, is believed to be the world’s first published study on a monkeypox-specific mRNA vaccine.

In this study, the research team tested three mRNA vaccines encoding the monkeypox proteins M1R and A35R, containing a combination of A35R-M1R fusions (VGPox1 and VGPox 2) and full-length encapsulated mRNAs of A35R and M1R. , tested VGPox 1-3 (VGPox 3).

Results showed that novel mRNA vaccines expressing fusion proteins composed of truncated A35R and full-length M1R could provide potent immunity and protection against poxviruses, and all three vaccines induced anti-A35R total IgG. I pointed out that On day 7 after one vaccination.

Specifically, VGPox 1 and VGPox 2 effectively induce high levels of both A35R and M1R IgG and are highly effective in neutralizing live virus infection in cell culture, but the two individual mRNA mixture (VGPox 3) does not neutralize. Studies show that VGPox 3 produced her M1R-specific antibodies so much later that serum collected at early time points failed to neutralize the virus.

Nonetheless, all three mRNA vaccines (VGPox 1-3) provide 100% protection against virus challenge assays. This is probably because all animals in the current study were challenged with live virus on his 36th day when both anti-A35R and anti-M1R neutralizing antibodies were present in all three of her vaccines. read the research.

We show that the vaccine can effectively induce both humoral and cellular immunity to the virus and fully protect mice subjected to lethal vaccinia virus challenge. Given the high degree of homology between vaccinia and monkeypox, it is suggested that VGPox may be a potential mRNA vaccine against monkeypox, the study concluded.

Monkeypox virus belongs to the genus Orthopoxvirus of the family Poxviridae, which also includes variola virus (smallpox) and vaccinia virus. The variola virus outbreak caused millions of deaths worldwide until it was eradicated globally in 1980, thanks to global vaccination with live viral preparations of the infectious vaccinia virus.

Cases of monkeypox infection increased worldwide this year, leading to a global epidemic declared as a global health emergency by the World Health Organization on 23 July. A total of 80,850 monkeypox cases have been reported worldwide as of November 23, according to the US Centers for Disease Control and Prevention.

The end of smallpox vaccination is one of the reasons causing the current outbreak of monkeypox virus, as the two viruses share highly homologous genomes and their antibodies show significant cross-protection. The study explained that it could be

Studies have shown that there are three pox vaccines currently available, named ACAM2000, a live VACV vaccine, modified vaccinia Ankara, and JYNNEOS. JYNNEOS was recently approved by the US Food and Drug Administration and is the primary vaccine for this year’s US monkeypox outbreak.

However, live virus vaccines express many viral proteins, many of which are not yet fully understood by researchers. people have some safety concerns.

Compared to attenuated virus vaccines, CNBG monkeypox-specific mRNA vaccines have proven to be safer for recipients.

This study showed that mice in all mRNA vaccine groups had no weight loss or other abnormalities after intranasal challenge with a lethal dose of vaccinia virus. Consistent with changes in body weight, the study showed that there was complete viral clearance in the lungs of these mice 9 days after nasal inoculation of the virus, whereas control animals had high viral loads in the lungs. it was done.

You may also like

Leave a Comment

Copyright ©️ All rights reserved. | Canadian Trends